A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2014.10.001
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2014
Authors
Publisher
Elsevier BV